Boosting with intranasal dendrimeric Aβ1-15 but not Aβ1-15 peptide leads to an effective immune response following a single injection of Aβ1-40/42 in APP-tg mice

Journal of Neuroinflammation

Volumn 3, Issue , 2006, Pages

  Seabrook, Timothy J ^a   Jiang, Liying ^a   Thomas, Katelyn ^a   Lemere, Cynthia A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-15]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA[1-7]; DENDRIMER; GLYCOPROTEIN; IMMUNOGLOBULIN G2B; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BRAIN HOMOGENATE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MIXTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MOUSE; NEUROLOGIC EXAMINATION; NONHUMAN; SINGLE DRUG DOSE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; WILD TYPE;

EID: 33747592100     PISSN: 17422094     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-3-14     Document Type: Article

References (46)

1. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
2. Golde TE: Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest 2003, 111:11-18.
3. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vendevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
4. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M. Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
5. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nature Neurosci 2002, 5:452-457.
6. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
7. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
8. Frenkel D, Maron R, Burt DS, Weiner HL: Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 2005, 115:2423-2433.
9. Schenk D: Amyloid-β Immunotherapy for Alzheimer's disease: the end of the beginning. Nature 2002, 3:824-828.
10. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
11. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L. Boada Rovira M, Forette F, Orgogozo JM: Clinical effects of A(beta) immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005.
12. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448-452.
13. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimers disease. Brain Pathol 2004, 14:11-20.
14. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D: Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131.
15. Geylis V, Kourilov V, Meiner Z, Nennesmo I, Bogdanovic N, Steinitz M: Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005, 26:597-606.
16. Lemere CA. Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004, 165:283-297.
17. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai P, Hancock WW, Weiner HL, Selkoe DJ: Nasal AB treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci 2000, 920:328-331.
18. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrdchyan M, Saing T, Cribbs DH: Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005, 174:1580-1586.
19. Seabrook TJ, Bloom JK, Iglesias M, Spooner ET, Walsh DM, Lemere CA: Species-specific immune response to immunization with human versus rodent A beta peptide. Neurobiol Aging 2004, 25:1141-1151.
20. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG: Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003, 15:505-514.
21. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL: Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003, 112:415-422.
22. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T: Epitope and isotype specificities of antibodies to beta-amyloid for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci 2003, 100:2023-2028.
23. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T: An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 2004, 24:6277-6282.
24. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T: Immunization with a non-toxi/non-fibrillar amyloid-ß homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001, 159:439-447.
25. Zhou J, Fonseca MI, Kayed R, Hernandez I, Webster SD, Yazan O, Cribbs DH, Glabe CG, Termer AJ: Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation 2005, 2:28.
26. Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA: Abeta 1-15 is less immunogenic than Abeta 1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting". Vaccine 2003, 21:2197-2206.
27. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L: High-level neuronal expression of Aß1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000, 20:4050-4058.
28. Walsh DM, Lomakin A, Benedek GB, Maggio JE, Condron MM, Teplow DB: Amylold b-protein fibrillogenesis: Detection of a protofibrillar intermediate. J Biol Chem 1997, 272:22364-22374.
29. Dickinson BL, Clements JD: Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995, 63:1617-1623.
30. Spooner ET, Desai RV, Mori C, Leverone JF, Lemere CA: The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol. Vaccine 2002, 21:290-297.
31. Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD: Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 2002, 23:991-1000.
32. Seabrook TJ, Iglesias M, Bloom JK, Spooner ET, Lemere CA: Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2FI mice. Vaccine 2004, 22:4075-4083.
33. Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA: Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Pathol 2000, 156:489-499.
34. Lemere CA, Blustzjan JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ: Sequence of deposition of heterogeneous amyloid b-peptides and Apo E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Disease 1996, 3:16-32.
35. Johnson-Wood K, Lee M, Motter & Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L: Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 1997, 94:1550-1555.
36. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ: Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000, 48:567-579.
37. Woodland DL: Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004, 25:98-104.
38. Tam JP: Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A 1988, 85:5409-5413.
39. Munesinghe DY, Clavijo P, Calle MC, Nussenzweig RS, Nardin E: Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein. Eur J Immunol 1991, 21:3015-3020.
40. Ciesielski MJ, Kazim AL, Barth RF, Fenstermaker RA: Cellular antitumor immune response to a branched iysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 2005, 54:107-119.
41. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM: Generation of antibodies for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002, 8:1270-1275.
42. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P, Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 2005, 58:430-435.
43. Maier M, Seabrook TJ, Lemere CA: Modulation of the humoral and cellular immune response in Albeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTIB) and E. coli enterotoxin LT(R192G). Vaccine 2005, 23:5149-5159.
44. Bayer AJ, Bullock P, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S: Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN 1792) in patients with AD. Neurology 2005, 64:94-101.
45. Unger WW, Jansen W, Wolvers DA, van Halteren AG, Kraal G, Samsom JN: Nasal tolerance induces antigen-specific CD4+CD25-regulatory T cells that can transfer their regulatory capacity to naive CD4+ T cells. Int immunol 2003, 15:731-739.
46. Unger WW, Hauet-Broere F, Jansen W, van Berkel LA, Kraal G, Samsom JN: Early events in peripheral regulatory T cell induction via the nasal mucosa. J Immunol 2003, 171:4592-4603.